SARS-CoV-2 Seroprevalence Among Healthcare Workers by Job Function and Work Location in a New York Inner-City Hospital.


Journal

Journal of hospital medicine
ISSN: 1553-5606
Titre abrégé: J Hosp Med
Pays: United States
ID NLM: 101271025

Informations de publication

Date de publication:
May 2021
Historique:
received: 17 12 2020
accepted: 31 03 2021
entrez: 30 4 2021
pubmed: 1 5 2021
medline: 20 5 2021
Statut: ppublish

Résumé

To describe the seroprevalence and risk for SARS-CoV-2 among healthcare workers (HCWs) by job function and work location following the pandemic's first wave in New York City (NYC). A cross-sectional study conducted between May 18 and June 26, 2020, during which HCWs at a large inner-city teaching hospital in NYC received voluntary antibody testing. The main outcome was presence of SARS-CoV-2 antibodies indicating previous infection. Seroprevalence and adjusted odds ratios (aORs) for seropositivity by type and location of work were calculated using logistic regression analyses. Of 2,749 HCWs tested, 831 tested positive, yielding a crude seroprevalence of 30.2% (95% CI, 29%-32%). Seroprevalence ranged from 11.1% for pharmacy staff to 44.0% for nonclinical HCWs comprised of patient transporters and housekeeping and security staff, with 37.5% for nurses and 20.9% for administrative staff. Compared to administrative staff, aORs (95% CIs) for seropositivity were 2.54 (1.64-3.94) for nurses; 2.51 (1.42-4.43) for nonclinical HCWs; between 1.70 and 1.83 for allied HCWs such as patient care technicians, social workers, registration clerks and therapists; and 0.80 (0.50-1.29) for physicians. Compared to office locations, aORs for the emergency department and inpatient units were 2.27 (1.53-3.37) and 1.48 (1.14-1.92), respectively. One-third of hospital-based HCWs were seropositive for SARS-CoV-2 by the end of the first wave in NYC. Seroprevalence differed by job function and work location, with the highest estimated risk for nurses and the emergency department, respectively. These findings support current nationwide policy prioritizing HCWs for receipt of newly authorized COVID-19 vaccines.

Identifiants

pubmed: 33929948
pii: jhm.3627
doi: 10.12788/jhm.3627
pmc: PMC8086991
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

282-289

Références

Thorax. 2020 Dec;75(12):1089-1094
pubmed: 32917840
Science. 2020 Jul 17;369(6501):297-301
pubmed: 32471856
JAMA. 2020 Sep 1;324(9):893-895
pubmed: 32780804
JAMA Intern Med. 2020 Dec 1;180(12):1707-1709
pubmed: 32780100
Ann Epidemiol. 2020 Aug;48:23-29.e4
pubmed: 32648546
Ethics Med Public Health. 2020 Jul-Sep;14:100546
pubmed: 32835061
JAMA. 2020 Dec 1;324(21):2155-2156
pubmed: 33185657
JAMA. 2020 Aug 4;324(5):441-442
pubmed: 32749495
Clin Microbiol Infect. 2021 Apr;27(4):511-519
pubmed: 33484843
Lancet Public Health. 2020 Sep;5(9):e475-e483
pubmed: 32745512
J Clin Virol. 2020 Jul;128:104437
pubmed: 32434708
Acta Odontol Scand. 2020 Nov;78(8):626-639
pubmed: 32881590
Int J Infect Dis. 2021 Jan;102:63-69
pubmed: 33075539
JAMA. 2020 Jul 7;324(1):94-96
pubmed: 32496504
N Engl J Med. 2020 Jun 25;382(26):2534-2543
pubmed: 32459916
MMWR Morb Mortal Wkly Rep. 2020 Oct 30;69(43):1569-1570
pubmed: 33119564
MMWR Morb Mortal Wkly Rep. 2020 Oct 30;69(43):1576-1583
pubmed: 33119554
JAMA Intern Med. 2020 Jul 21;:
pubmed: 32692365
Proc Natl Acad Sci U S A. 2020 Jun 30;117(26):14857-14863
pubmed: 32527856
Clin Infect Dis. 2020 Jul 06;:
pubmed: 32628750
Int J Environ Res Public Health. 2020 Apr 23;17(8):
pubmed: 32340347
Lancet. 2020 Sep 25;:
pubmed: 32987007
Postgrad Med. 2020 Aug;132(6):489-494
pubmed: 32331509
Euro Surveill. 2020 Apr;25(14):
pubmed: 32290904
JAMA. 2020 May 12;323(18):1837-1838
pubmed: 32215590
MMWR Morb Mortal Wkly Rep. 2020 Sep 04;69(35):1221-1226
pubmed: 32881855
Public Health. 2020 Jun;183:110-111
pubmed: 32502699
JAMA. 2020 Jul 14;324(2):195-197
pubmed: 32539107
Infect Control Hosp Epidemiol. 2020 Dec;41(12):1466-1467
pubmed: 32576336
Biomed J. 2020 Aug;43(4):328-333
pubmed: 32387617
N Engl J Med. 2020 Dec 31;383(27):2603-2615
pubmed: 33301246

Auteurs

Murli U Purswani (MU)

Division of Pediatric Infectious Disease, Department of Pediatrics, BronxCare Health System, Bronx, NY.

Jessica Bucciarelli (J)

Department of Family Medicine, Bronx-Care Health System Bronx, NY.

Jose Tiburcio (J)

Department of Family Medicine, Bronx-Care Health System Bronx, NY.

Shamuel M Yagudayev (SM)

Department of Family Medicine, Bronx-Care Health System Bronx, NY.

Georgia H Connell (GH)

Patient Care Services, Ambulatory Care, BronxCare Health System Bronx, NY.

Arafat A Omidiran (AA)

Department of Family Medicine, Bronx-Care Health System Bronx, NY.

Launcelot Hannaway (L)

Department of Family Medicine, Bronx-Care Health System Bronx, NY.

Cosmina Zeana (C)

Division of Adult Infectious Disease, Department of Medicine, BronxCare Health System, Bronx, NY.

Maureen Healy (M)

Department of Family Medicine, Bronx-Care Health System Bronx, NY.

Gary Yu (G)

Rory Meyers College of Nursing, New York University, New York, NY.

Doug Reich (D)

Department of Family Medicine, Bronx-Care Health System Bronx, NY.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH